home-slide-2
Focused on Patients The Anaptys Team works to transform patient health by delivering innovative immunology therapeutics. The Anaptys team works to transform patient health by delivering innovative immunology therapeutics.
Theresa, working in the Anaptys lab
home-slide-2
Anaptys Overview A clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases. We are a clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases.
Sarah and Ben in an Anaptys conference room
home-slide-2
The Anaptys Difference Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance. Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance.
home-slide-2
Transparency, Accountability, Humility Embracing our core values to guide our efforts discovering and developing medicines that transform patient lives. Embracing our core values to guide our efforts discovering and developing medicines that transform patient lives.
May and Annie, reviewing a recent Immunology publication
home-slide-2
Webcast Anaptys provides overview of ANB032 a BTLA agonist, at virtual R&D event Anaptys provides overview of ANB032 a BTLA agonist, at virtual R&D event Latest Events

Press Releases

May 9, 2024
  • Anaptys News

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

May 9, 2024
  • Anaptys News

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP), a severe orphan disease that is potentially life-threatening if left untreated.

May 9, 2024
  • Anaptys News

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the execution of an amended agreement with Sagard Healthcare for additional Anaptys Jemperli (dostarlimab) royalties.